SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn’s Disease in Journal of Crohn’s and Colitis

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the publication of data from a multicenter European clinical trial evaluating the safety and efficacy of neuroimmune modulation in patients with treatment-refractory Crohn’s disease in…

Read MoreSetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn’s Disease in Journal of Crohn’s and Colitis

Integral Launches Privacy Workbench to Revolutionize Data Quality and Certification

Integral, an innovator in safeguarding privacy and maximizing data quality, today announced the launch of its privacy analytics suite, Privacy Workbench. The privacy analytics suite adds to defense-in-depth security strategies while allowing fast and carefully controlled review processes for companies…

Read MoreIntegral Launches Privacy Workbench to Revolutionize Data Quality and Certification

Thrive Health Places No. 21 on The Globe and Mail’s Fifth-Annual Ranking of Canada’s Top Growing Companies

Thrive Health is pleased to announce it placed No. 21 on the 2023 Report on Business ranking of Canada’s Top Growing Companies. In total, 425 companies earned a spot on this year’s ranking. Thrive Health, a leader in Canadian healthcare…

Read MoreThrive Health Places No. 21 on The Globe and Mail’s Fifth-Annual Ranking of Canada’s Top Growing Companies

FineHeart Obtains Czech Health Authority Approval to Commence First in Human Clinical Study

FineHeart S.A, a medical device company developing innovative devices for cardiology announced today that it has received authorization from the SUKL (the Czech Republic State Institute for the Control of Medicinal Products) to carry out “A prospective, single arm, single…

Read MoreFineHeart Obtains Czech Health Authority Approval to Commence First in Human Clinical Study

Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific

Lokavant, the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co. Ltd. to expand its AI-optimized platform across the Asia-Pacific (APAC) region. One of Lokavant’s earliest customers, CMIC Group, is the…

Read MoreLokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

AbbVie (NYSE: ABBV) today announced data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more…

Read MoreAbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review a new Biologics License Application (BLA) for sotatercept, Merck’s novel investigational activin…

Read MoreMerck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)